DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Phase 2

Completed

Conditions: Biliary Cancer
Cholangiocarcinoma

Interventions: Drug: Gemcitabine, Irinotecan, Panitumumab

First Posted Date: 2009-07-29

Last Posted Date: 2020-03-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 35

Registration Number: NCT00948935

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Phase 1

Completed

Conditions: Graft-versus-host Disease
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Maraviroc 150 MG
Drug: Maraviroc 300 mg Phase II
Drug: Maraviroc 300 mg

First Posted Date: 2009-07-29

Last Posted Date: 2022-05-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 38

Registration Number: NCT00948753

Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: nelfinavir mesylate
Drug: temozolomide
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2009-06-08

Last Posted Date: 2019-04-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 15

Registration Number: NCT00915694

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2009-05-29

Last Posted Date: 2019-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT00909831

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

Not Applicable

Completed

Conditions: Healthy, no Evidence of Disease
Breast Cancer

Interventions: Behavioral: exercise intervention
Other: counseling intervention
Other: gas chromatography
Other: immunoenzyme technique
Other: immunologic technique
Other: laboratory biomarker analysis
Other: mass spectrometry
Other: physiologic testing
Other: questionnaire administration
Other: survey administration
Procedure: dual x-ray absorptometry
Procedure: magnetic resonance imaging
Procedure: study of high risk factors

First Posted Date: 2009-05-04

Last Posted Date: 2020-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 183

Registration Number: NCT00892515

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Phase 2

Completed

Conditions: Follicular Lymphoma
Marginal Zone B-Cell Lymphoma
MALT Lymphoma
Lymphoma of Mucosa-Associated Lymphoid Tissue
Lymphoma, Small Lymphocytic
Waldenstrom Macroglobulinemia
Mantle-Cell Lymphoma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2008-10-31

Last Posted Date: 2023-03-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT00783367

Locations: 🇺🇸
University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania, United States

Infusional C-myb ASODN in Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: c-myb AS ODN

First Posted Date: 2008-10-27

Last Posted Date: 2016-09-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 13

Registration Number: NCT00780052

Locations: 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

Phase 1

Completed

Conditions: AML
Myeloid Leukemias
Leukemia
CML

Interventions: Drug: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
Drug: Rapamycin + MEC

First Posted Date: 2008-10-27

Last Posted Date: 2019-07-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 16

Registration Number: NCT00780104

Locations: 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

Phase 1

Terminated

Conditions: Burkitt's Lymphoma
ALL
Lymphoblastic Leukemia
CML

Interventions: Drug: Rapamycin + high dose etoposide and cytarabine

First Posted Date: 2008-10-21

Last Posted Date: 2020-04-21

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 4

Registration Number: NCT00776373

Locations: 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2008-07-17

Last Posted Date: 2014-01-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT00717587

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy